• Algae-based microrobots can effectively deliver medicine to the lungs, bypassing natural defenses like mucus and macrophages.
• In tests on MRSA-infected mice, the microrobot treatment resulted in a 100% survival rate, compared to zero survival with traditional methods or no treatment.
• The technology has also been used to deliver chemotherapy drugs to mice with metastatic lung tumors, and human trials are expected.

Researchers at UC San Diego have developed microrobots made from green algae to deliver drugs directly to the lungs, overcoming the body's natural defense mechanisms. The lungs are constantly exposed to threats, but also protected by barriers that make drug delivery difficult. These algae-based microrobots are coated with cell membranes, allowing them to evade immune responses and distribute medication evenly throughout the lungs. This innovative approach has shown promise in treating pneumonia in mice and delivering chemotherapy for lung tumors, potentially leading to more effective treatments with fewer side effects.

• What: Microrobots made of green algae are used to deliver drugs directly to the lungs, bypassing natural defense mechanisms.
• Who: Joseph Wang and Liangfang Zhang (UC San Diego Jacobs School of Engineering) led the research team.
• When: Study published in Nature Communications, Reported May 7, 2025.
• Where: Research conducted at UC San Diego, testing done on mice.

The development of algae-based microrobots for targeted drug delivery to the lungs represents a significant advancement in the treatment of respiratory diseases. By bypassing the body's natural defenses and delivering medication directly to the affected area, this technology has the potential to improve treatment outcomes and reduce side effects. The success of the treatment in mice models suggests that this approach holds promise for future human trials. The fact that the microrobots are made of algae, a biocompatible material, further enhances the appeal of this technology.

The use of algae microrobots for drug delivery to the lungs presents a promising new approach for treating respiratory diseases. The technology has shown significant success in animal models, and the anticipation of human trials indicates a potential shift in how lung infections and tumors are treated in the future. Further research and clinical trials will be necessary to fully assess the safety and efficacy of this innovative method.